Clozapine response trajectories and predictors of non-response in treatment-resistant schizophrenia: a chart review study

No abstract is available for this paper.

• Publication year

  2019

• Venue

  European Archives of Psychiatry and Clinical Neuroscience

• Publication date

  2019-08-19

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1007/s00406-019-01053-6PMID 31428862
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Glutamatergic Neurometabolite Levels in Patients With Ultra-Treatment-Resistant Schizophrenia: A Cross-Sectional 3T Proton Magnetic Resonance Spectroscopy Study.

  2019cited by this paper
• The impact of delay in clozapine initiation on treatment outcomes in patients with treatment-resistant schizophrenia: A systematic review.

  2018cited by this paper
• Treatment resistant schizophrenia – review and a call to action

  2018cited by this paper
• Maintenance doses for clozapine: past and present

  2018cited by this paper
• Clozapine use in early psychosis.

  2018cited by this paper
• Repeated Clozapine Increases the Level of Serotonin 5-HT1AR Heterodimerization with 5-HT2A or Dopamine D2 Receptors in the Mouse Cortex

  2018cited by this paper
• How Many Patients With Schizophrenia Do Not Respond to Antipsychotic Drugs in the Short Term? An Analysis Based on Individual Patient Data From Randomized Controlled Trials

  2018cited by this paper
• Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia

  2018cited by this paper
• Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology.

  2017cited by this paper
• Clozapine Response Rates among People with Treatment-Resistant Schizophrenia: Data from a Systematic Review and Meta-Analysis

  2017cited by this paper
• The critical treatment window of clozapine in treatment-resistant schizophrenia: Secondary analysis of an observational study.

  2017cited by this paper
• Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence

  2017cited by this paper
• Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors

  2017cited by this paper
• Schizophrenia

  2016cited by this paper
• Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses

  2016cited by this paper
• Antipsychotic-induced sensitization and tolerance: Behavioral characteristics, developmental impacts, and neurobiological mechanisms

  2016cited by this paper
• Correlation between delay in initiating clozapine and symptomatic improvement.

  2015cited by this paper
• Clozapine use reduced psychiatric hospitalization and emergency room visits in patients with bipolar disorder independent of improved treatment regularity in a three‐year follow‐up period

  2015cited by this paper
• Neuroimaging findings in treatment-resistant schizophrenia: A systematic review: Lack of neuroimaging correlates of treatment-resistant schizophrenia.

  2015cited by this paper
• Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.

  2015cited by this paper
• Delayed initiation of clozapine may be related to poor response in treatment-resistant schizophrenia

  2015cited by this paper
• Early Improvement As a Predictor of Later Response to Antipsychotics in Schizophrenia: A Diagnostic Test Review.

  2015cited by this paper
• Treatment-resistant schizophrenia: challenges and implications for clinical practice.

  2015cited by this paper
• Duration of untreated psychosis as predictor of long-term outcome in schizophrenia: systematic review and meta-analysis

  2014cited by this paper
• Clinical predictors of therapeutic response to antipsychotics in schizophrenia

  2014cited by this paper
• Clozapine: a review of clinical practice guidelines and prescribing trends

  2014cited by this paper
• Glutamate-mediated excitotoxicity in schizophrenia: a review.

  2014cited by this paper
• Mortality, attempted suicide, re‐hospitalisation and prescription refill for clozapine and other antipsychotics in Sweden—a register‐based study

  2014cited by this paper
• The neurobiology of relapse in schizophrenia.

  2014cited by this paper
• Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function.

  2014cited by this paper
• Schizophrenia resistance ( is there a difference

  2013cited by this paper
• Treating older adults with schizophrenia: challenges and opportunities.

  2013cited by this paper
• The nature of relapse in schizophrenia

  2013cited by this paper
• Using treatment response to subtype schizophrenia: proposal for a new paradigm in classification.

  2013cited by this paper
• Treatment-Resistant Schizophrenia: Prevalence and Risk Factors

  2013cited by this paper
• Neurodevelopment and inflammatory patterns in schizophrenia in relation to pathophysiology.

  2013cited by this paper
• Glutamate in schizophrenia: a focused review and meta-analysis of ¹H-MRS studies.

  2013cited by this paper
• Supersensitivity psychosis in a case with clozapine tolerance.

  2012cited by this paper
• Predictors of Clozapine Response in Patients With Treatment-Refractory Schizophrenia: Results From a Danish Register Study

  2012cited by this paper
• Beyond Dopamine: Glutamate as a Target for Future Antipsychotics

  2012cited by this paper
• Divergent trajectories of physical, cognitive, and psychosocial aging in schizophrenia.

  2011cited by this paper
• Treatment resistant schizophrenia and response to antipsychotics: a review.

  2011cited by this paper
• Changes in cortical thickness during the course of illness in schizophrenia.

  2011cited by this paper
• An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis.

  2011cited by this paper
• What is schizophrenia: A neurodevelopmental or neurodegenerative disorder or a combination of both? A critical analysis

  2010cited by this paper
• Patterns of clozapine prescribing in a mental health service in New Zealand

  2010cited by this paper
• Effects of acute metabolic stress on the dopaminergic and pituitary-adrenal axis activity in patients with schizophrenia, their unaffected siblings and controls.

  2008cited by this paper
• Atypical Antipsychotics: CATIE Study, Drug-Induced Movement Disorder and Resulting Iatrogenic Psychiatric-Like Symptoms, Supersensitivity Rebound Psychosis and Withdrawal Discontinuation Syndromes

  2008cited by this paper
• Clinical predictors of therapeutic response to clozapine in a sample of Turkish patients with treatment-resistant schizophrenia.

  2007cited by this paper
• The "delayed onset" of antipsychotic action--an idea whose time has come and gone.

  2006cited by this paper
• Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal‐related relapse

  2006cited by this paper
• Predictors and markers of clozapine response

  2005influential reference
• Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review.

  2005cited by this paper
• Predictors of response in a sample of treatment-resistant psychotic patients on clozapine

  2004cited by this paper
• Supersensitivity psychosis in schizophrenic patients after sudden clozapine withdrawal

  2004cited by this paper
• Predictors of response in a sample of treatment-resistant psychotic patients on clozapine

  2004cited by this paper
• Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study.

  2003cited by this paper
• Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality.

  2003cited by this paper
• Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia.

  2002cited by this paper
• Clozapine Impact on Clinical Outcomes and Aggression in Severely Ill Adolescents with Childhood-Onset Schizophrenia

  2001cited by this paper
• Double-blind study of clozapine dose response in chronic schizophrenia.

  1999cited by this paper
• Auditory event-related potential indices of fronto-temporal information processing in schizophrenia syndromes: valid outcome prediction of clozapine therapy in a three-year follow-up.

  1999cited by this paper
• Development, disease and degeneration in schizophrenia: a unitary pathophysiological model.

  1999cited by this paper
• Clozapine therapy for older veterans.

  1998cited by this paper
• Treatment-resistant schizophrenia--the role of clozapine.

  1997cited by this paper
• Clozapine Withdrawal: Serotonergic or Dopaminergic Mechanisms?-Reply

  1997cited by this paper
• Clozapine withdrawal: serotonergic or dopaminergic mechanisms?

  1997cited by this paper
• A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.

  1997cited by this paper
• A Clinical Study of Clozapine Treatment and Predictors of Response in a Canadian Sample

  1995cited by this paper
• Predictors of clozapine response in schizophrenia.

  1994cited by this paper
• Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome.

  1994cited by this paper
• Can clozapine response be predicted? A naturalistic pilot study.

  1993cited by this paper
• Anti-glutamatergic effects of clozapine.

  1993cited by this paper
• Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine

  1991cited by this paper
• Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia.

  1991cited by this paper
• Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

  1988cited by this paper
• Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics.

  1980cited by this paper

• Efficacy and tolerability of pharmacological interventions for schizophrenia non-responsive to prior treatment: a systematic review and network meta-analysis

  2025cites this paper
• Factors Associated with Poor Response to Clozapine in Patients with Treatment-resistant Schizophrenia

  2025cites this paper
• Clozapine delay results in poorer outcomes for treatment resistant schizophrenia patients

  2024cites this paper
• Clozapine treatment and astrocyte activity in treatment resistant schizophrenia: A proton magnetic resonance spectroscopy study.

  2024cites this paper
• Response to clozapine and its predictors in treatment-resistant schizophrenia spectrum disorders: A retrospective chart review.

  2024cites this paper
• Aberrant connectivity in the hippocampus, bilateral insula and temporal poles precedes treatment resistance in first-episode psychosis: a prospective resting-state functional magnetic resonance imaging study with connectivity concordance mapping

  2024cites this paper
• Elevated intrinsic cortical curvature in treatment-resistant schizophrenia: Evidence of structural deformation in functional connectivity areas and comparison with alternate indices of structure.

  2024cites this paper
• Predicting treatment resistance in positive and negative symptom domains from first episode psychosis: Development of a clinical prediction model.

  2024cites this paper
• Lost in Translation: Challenges in the Diagnosis and Treatment of Early-Onset Schizophrenia

  2023influential citation
• Developing prediction models for symptom severity around the time of discharge from a tertiary-care program for treatment-resistant psychosis

  2023cites this paper
• Pharmacogenomic screening for agranulocytosis and efficacy with clozapine

  2023cites this paper
• Response prediction in treatment of patients with schizophrenia after switching from oral aripiprazole to aripiprazole once-monthly.

  2023cites this paper
• Enhancing Predictive Power: Integrating a Linear Support Vector Classifier with Logistic Regression for Patient Outcome Prognosis in Virtual Reality Therapy for Treatment-Resistant Schizophrenia

  2023cites this paper
• Deconstructing the genetic architecture of treatment-resistant schizophrenia in East Asian ancestry.

  2023cites this paper
• Antipsychotic Use: Cross-Sectional Opinion Survey of Psychiatrists in India and United Kingdom

  2023cites this paper
• Feasibility and Effect of Increasing Clozapine Plasma Levels in Long-Stay Patients With Treatment-Resistant Schizophrenia

  2023cites this paper
• The importance of early and proactive use of long-acting injectable antipsychotics in the management of schizophrenia.

  2023cites this paper
• Second to none: rationale, timing, and clinical management of clozapine use in schizophrenia

  2023cites this paper
• Long-Term Outcome of Clozapine in Treatment-Resistant Schizophrenia

  2023cites this paper
• Identification of novel functional brain proteins for treatment-resistant schizophrenia: Based on a proteome-wide association study

  2023cites this paper
• The ever-growing case for clozapine in the treatment of schizophrenia: an obligation for psychiatrists and psychiatry

  2023cites this paper
• Managing treatment resistance in schizophrenia: A joint study in Hong Kong and Singapore

  2022cites this paper
• Interaction Testing and Polygenic Risk Scoring to Estimate the Association of Common Genetic Variants With Treatment Resistance in Schizophrenia

  2022cites this paper
• Using a statistical learning approach to identify sociodemographic and clinical predictors of response to clozapine

  2022influential citation
• Relationship between plasma clozapine/N-desmethylclozapine and changes in basal forebrain-dorsolateral prefrontal cortex coupling in treatment-resistant schizophrenia.

  2022cites this paper
• An international clozapine titration guideline to increase its safety and move forward on the route started by German-speaking psychiatrists in the 1960s

  2022influential citation
• Dopaminergic dysfunction and excitatory/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment

  2022cites this paper
• Pharmacogenomics of Clozapine-induced agranulocytosis: a systematic review and meta-analysis

  2022cites this paper
• Factors Associated With Poor Response to Clozapine in Schizophrenia

  2022cites this paper
• Clozapine Use and Forensic Outcomes in Psychiatric Inpatients Deemed Incompetent to Stand Trial

  2022cites this paper
• Gamma‐aminobutyric acid (GABA) levels in the midcingulate cortex and clozapine response in patients with treatment‐resistant schizophrenia: A proton magnetic resonance spectroscopy (1H‐MRS) study

  2022cites this paper
• A predictor model of treatment resistance in schizophrenia using data from electronic health records

  2022cites this paper
• Decreased cortical gyrification and surface area in the left medial parietal cortex in patients with treatment‐resistant and ultratreatment‐resistant schizophrenia

  2022cites this paper
• Dopamine supersensitivity psychosis and delay of clozapine treatment in patients with treatment-resistant schizophrenia

  2022cites this paper
• Demographic and clinical variables associated with response to clozapine in schizophrenia: a systematic review and meta-analysis

  2021influential citation
• Clinical predictors of response to clozapine in Tunisian patients with treatment resistant schizophrenia.

  2021cites this paper
• Effect of Delayed Clozapine Initiation on Acute Treatment Response in Treatment-Resistant Schizophrenia

  2021cites this paper
• Possible pharmacogenetic factors in clozapine treatment failure: a case report

  2021cites this paper
• Predictors of response to pharmacological treatments in treatment-resistant schizophrenia - A systematic review and meta-analysis.

  2021cites this paper
• Longitudinal course of cognition in schizophrenia: Does treatment resistance play a role?

  2021cites this paper
• Prevalence and predictors of treatment-resistant schizophrenia in a tertiary hospital in Northeast Brazil.

  2021cites this paper
• Predictors of Treatment-Resistant and Clozapine-Resistant Schizophrenia: A 12-Year Follow-up Study of First-Episode Schizophrenia-Spectrum Disorders.

  2020cites this paper
• Quantitative biomarkers to predict response to clozapine treatment using resting EEG data.

  2020cites this paper
• Commentary: More research needed on predictive biomarkers related to clozapine treatment

  2019cites this paper
• Glutamatergic Neurometabolite Levels in Patients With Ultra-Treatment-Resistant Schizophrenia: A Cross-Sectional 3T Proton Magnetic Resonance Spectroscopy Study.

  2019cites this paper